# A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT06441682** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **argenx** · enrollment: 60 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** ARGX-119
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06441682
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441682, "A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06441682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*